Bio Istanbul is a US$2.2bn (拢1.4bn) biomedical science park with a children鈥檚 hospital and sustainable residential community.
Davis Langdon will provide specialist healthcare cost and programme management services in collaboration with Aecom鈥檚 engineering team to help realise the first community in Turkey built to meet internationally certified sustainability standards.
The 192ha site will include the tertiary care children鈥檚 hospital, biomedical research and development facilities, and complementary commercial, retail and residential clusters. Bio Istanbul is designed to accommodate 15,000 residents and a further 35,000 working commuters. Companies will include pharmaceutical, medical technology and biomedical informatics companies.
Davis Langdon had worked closely with the client throughout the initial feasibility studies and financial due diligence stages of the project before the latest construction cost and programme management appointment. The project also involves Aecom鈥檚 engineering team, which is working with a technology company that is designing and implementing the IT 鈥榮mart city鈥� infrastructure and will also be one of Bio Istanbul鈥檚 first flagship tenants. The 鈥榮mart city鈥� infrastructure initiatives are designed to ensure efficient use of energy and facilities and provide an integrated transport network with an intra-site public tramway and a comprehensive site security system.
Drew Carr-Ellison, chief operating officer for BCDco, said: 鈥淏io Istanbul is an ambitious and exceptional project which will transform paediatric healthcare and biomedical research and development in Turkey and the surrounding regions. To take one example, the Turkish pharmaceutical industry today spends approximately $40 million per year on R&D. When compared with the $10+ billion spent in each of the major Western economies, the importance of the project to Turkey鈥檚 transition to a knowledge-based economy becomes clear."
Philip Hynard, a director in Davis Langdon鈥檚 healthcare team, said: 鈥淭his is a truly innovative project that will provide the most advanced healthcare and research facilities for the people of Turkey. Having the opportunity to work on a scheme that transcends conventional boundaries, and one which will provide a new quality benchmark across the globe, is very exciting for the entire Aecom family.鈥�
Stage 1 in the development of Bio Istanbul will begin this month and will see the masterplan for the site designed, with construction due to begin on site in the summer of 2012. Davis Langdon is also working with BCDco on schemes in Asia, the Middle East and Europe.
Got a story? Email news@theconstructionindex.co.uk
